Catalyst
Slingshot members are tracking this event:
Phase 3 data of Auryxia for Iron deficiency anemia in non-dialysis dependent CKD patients due early 2Q 2016. April 30 is a BPC estimate based on early 2Q guidance
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| KERX | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 29, 2016
Occurred Source:
http://investors.keryx.com/phoenix.zhtml?c=122201&p=irol-newsArticle&ID=2151305
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3 Study In Pancreatic Cancer, Auryxia, Iron Deficiency, Anemia, Ckd, 2q
